Embryonal cancer can arise from postnatally persistent embryonal remnant or rest cells, which are uniquely characterized by the absence of p53 mutations. Perinatal overexpression of the MycN oncoprotein in embryonal cancer precursor cells causes postnatal rests, and later tumor formation through unknown mechanisms. However, overexpression of Myc in adult tissues normally activates apoptosis and/or senescence signals as an organismal defense mechanism against cancer. Here, we show that perinatal neuroblastoma precursor cells exhibited a transiently diminished p53 response to MycN oncoprotein stress and resistance to trophic factor withdrawal, compared with their adult counterpart cells from the TH-MYCN þ / þ transgenic mouse model of neuroblastoma. The adult stem cell maintenance factor and Polycomb group protein, Bmi1 (B-cell-specific Moloney murine leukemia virus integration site), had a critical role at neuroblastoma initiation in the model, by repressing p53 responses in precursor cells. We further show in neuroblastoma tumor cells that Bmi1 could directly bind p53 in a complex with other Polycomb complex proteins, Ring1A or Ring1B, leading to increased p53 ubiquitination and degradation. Repressed p53 signal responses were also seen in precursor cells for other embryonal cancer types, medulloblastoma and acute lymphoblastic leukemia. Collectively, these date indicate a general mechanism for p53 inactivation in some embryonal cell types and consequent susceptibility to MycN oncogenesis at the point of embryonal tumor initiation.
INTRODUCTION
Neuroblastoma and medulloblastoma are embryonal childhood tumors of the peripheral and central nervous systems, respectively. 1, 2 The early onset of the disease and the potential of some neuroblastoma cell lines to differentiate into several distinct cell types in vitro, point to neuroblastoma as a disease of neural crest-derived stem cells. 3, 4 Medulloblastoma arises from granule neurone precursors (GNPs) of the developing cerebellum. 5 The mechanism of embryonal cancer initiation is unknown.
During normal embryonal neurodevelopment there is high proliferation and migration of neural crest cells, however, only 15-40% of post-migratory cells survive to form mature neural tissues. 6 Postnatally persistent embryonal cells with tumorigenic capacity must possess both the capacity to resist cell death imposed by trophic factor withdrawal during the final stages of neurodevelopment and undergo secondary changes that characterize later tumor promotion and progression.
We have previously shown that perinatal MycN oncoprotein expression in neuroblastoma and medulloblastoma precursor cells can cause postnatal neuroblast and GNP hyperplasia, respectively, which are initiating events in these diseases. 7, 8 MycN belongs to the Myc family of transcription factors and, although commonly overexpressed by many human cancers, its regulated expression is essential for the development of the nervous system. 9 A peculiarity of Myc proteins is their capacity to both enhance cell proliferation and survival through influences on the cell cycle, and conversely, sensitize cells for apoptosis through mechanisms such as p53 upregulation and/or activation. 10, 11 Indeed, p53 has recently been identified as a MycN target gene, and the ability of MycN to sensitize cells for p53-mediated apoptosis acts is a safeguard against cancer. 12 These data suggest that MycN upregulation cannot be solely responsible for embryonal tumor initiation, and that additional factors are required to block p53-mediated apoptosis.
Several mechanisms have already been suggested to explain p53 downregulation in neuroblastoma, including upregulation of MDM2 (murine double minute) and Bmi1 (B-cell-specific Moloney murine leukemia virus integration site). 13, 14 Although MDM2 is a major regulator of p53, MDM2 amplification has been seen in only 2% of neuroblastoma 15 and p53/MDM2 pathway repression is most evident at relapse, 16 suggesting that MDM2-independent mechanisms are likely to be involved in the inhibition of cell death in neuroblastoma at the initiation stage. Bmi1 was first described as an oncogene cooperating with c-Myc during the initiation of lymphomas 17, 18 and its upregulation has frequently been observed in many human cancers, 19 including neuroblastoma. 13, 20 Bmi1 expression has an important role in both the development and maintenance of cancer stem cells by conferring on them stem-like properties, such as resistance to death signaling. 21 Some molecular mechanisms underlying the regulation of apoptosis and differentiation by Bmi1 have been proposed, such as repression of the tumor suppressors p16 INK4a and p19 ARF (p14 ARF in humans), 19 but other mechanisms are likely to be involved.
Here, we identified a novel mechanism for Bmi1-mediated inactivation of apoptotic barriers. Bmi1 reduced p53 protein levels by directly inducing its polyubiquitination and proteasomal degradation. Bmi1 repressed p53 responses in neuroblastoma precursor cells, suggesting some specialised perinatal cells exposed to an oncogenic MycN signal can resist cell death and persist postnatally due to an inherent regulatory effect of Bmi1 on p53 stress responses. These results suggest that drugs targeting Bmi1 activity may restore p53 activation, causing subsequent tumor cell death in vivo, and hence may have an important impact in the design of future therapeutic strategies for child cancer prevention.
RESULTS

MycN protects neuroblastoma precursor cells from death stimuli
In the TH-MYCN þ / þ transgenic mouse model of neuroblastoma, MycN oncoprotein expression is targeted to the neural crest, thereby inducing neuroblastoma development with a phenotypic, biochemical and cytogenetic profile very similar to the human disease. 22 Importantly, this model fully recapitulates the p53 wildtype (WT) status, chemosensitivity and p53-dependent apoptotic responses of human neuroblastoma. 23, 24 We first used neuroblastoma precursor cells (that is, perinatal primary sympathetic ganglia from the TH-MYCN þ / þ mice) to investigate the effects of MycN expression on the response to death stimuli and the replicative potential of these precancer cells.
We found that cultured paravertebral ganglia cells from 2-weekold homozygote TH-MYCN þ / þ transgenic mice were resistant to cell death caused by the withdrawal of nerve growth factor, the trophic factor for sympathetic nervous tissue, when compared with normal WT controls (Figure 1a) . Perinatal ganglia cells from normal mice or rats infected with a MycN-expressing adenoviral vector in vitro also demonstrated resistance to nerve growth factor withdrawal, indicating that death resistance in TH-MYCN þ / þ ganglia cells was caused by MycN expression and not factors specific to the transgene (Figure 1b) . Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) immunofluorescence indicated that MycN expression blocked the apoptotic response of neuroblastoma precursor cells (Figure 1c) . Furthermore, we analyzed two key molecules in terminal stages of apoptosis: the activation of caspase-activated deoxyribonuclease (CAD), which is responsible for inter-nucleosomal DNA cleavage; and, the release of the apoptosis-inducing factor (AIF), which stimulates chromatin condensation. When MycN-expressing cells were exposed to apoptotic stimuli, we observed inhibition of CAD activation and thus inability to translocate from the cytoplasm to the nucleus (Figure 1d ). We also observed little mitochondrial release and translocation of AIF to the nucleus in MycN-expressing cells (Figure 1e ). The protective effect of MycN was also seen when ganglia were exposed to other noxious stimuli, such as serum withdrawal or hypoxia in vitro (Supplementary Figure S1) . TH-MYCN þ / þ mice were then injected with 5-bromo-2'-deoxyuridine at 2 weeks of age and neuroblast replication in vivo was assessed by immunohistochemistry in paravertebral ganglia. As expected, MycN expression caused a marked increase in neuroblast replication compared with WT controls (Figure 1f ).
We next examined whether the protective effect of a MycN signal could also be conferred upon the mature postnatal cells developing from perinatal neuroblasts. In stark contrast, MycN overexpression in neuroblastoma tumor cell lines (NHO2A cells) derived from TH-MYCN þ / þ mouse tumors, 23 or primary ganglia cells from 6-week-old WT mice, caused marked cell death in the absence of trophic factor (Figure 1g ). These results suggested that the barriers present in normal adult cells exposed to oncoprotein stress were transiently and specifically repressed in perinatal neuroblasts.
Neuroblastoma precursor cells exhibit transient repression of the p53 signal response to MycN oncoprotein stress An important determinant of Myc-induced apoptosis is the p53 stress response signal. 25 Deleting p53 from TH-MYCN þ / þ mice has recently been shown to enhance tumorigenicity. 24 We evaluated p53 responses to growth factor withdrawal by culturing ganglia from 6-week-old WT, 2-week-old WT or 2-week-old TH-MYCN þ / þ mice, subjecting them to growth factor deprivation, and assaying p53 expression by immunofluorescence. Mature ganglia cells from 6-week-old WT mice showed robust p53 responses. In contrast, perinatal 2-week WT ganglia cells exhibited a twofold reduction in p53 responses, while 2-week TH-MYCN þ / þ ganglia responses were threefold lower than 6-week-old WT ganglia (Figure 2a and Supplementary Figure  S2a) . Although exogenous p53 overexpression, restored cell death in the presence or absence of trophic factor in perinatal ganglia cells from both WT and TH-MYCN þ / þ mice (Figure 2b ), the MDM2 inhibitor, Nutlin-3A, only partially restored death sensitivity in (Figure 2c ). In contrast, treatment with quinacrine, known to activate p53 through an MDM2-independent mechanism, 26 restored p53 expression (Supplementary Figure S2b) and death sensitivity (Figure 2c ) after trophic factor withdrawal in 2-week-old TH-MYCN þ / þ ganglia. These results suggested that MycN protects neuroblastoma precursor cells from cell death induced by trophic factor withdrawal through MDM2-independent repression of the p53.
Bmi1 has a critical role in neuroblastoma tumor initiation We next investigated the relative roles of Bmi1 and MDM2 as potential negative regulators of the p53 stress signal response in neuroblastoma precursor cells. We showed that Mdm2 mRNA levels were not markedly increased when ganglia cells from 2-week WT, 2-week TH-MYCN þ / þ and tumor tissue from TH-MYCN þ / þ mice were compared with mature ganglia cells from 6-week WT mice (Figure 3a ). This data further support an MDM2-independent mechanism of p53 signal repression. In contrast, we found Bmi1 mRNA expression demonstrated a marked and stepwise increase in 2-week-old ganglia and tumor tissue from TH-MYCN þ / þ mice in comparison with their WT counterparts (Figure 3a) . The oncogenic function of Bmi1 has been attributed to the transcriptional repression of the Ink4a/ARF (alternate reading frame) locus coding for the p16
Ink4a and p19/p14 ARF tumor suppressors. 19 In agreement, we showed that relative p16
Ink4a mRNA levels were inversely proportional to the relative levels of Bmi1 mRNA expression (Figures 3a and b) . In contrast, we found a higher p19 ARF level in ganglia from 2-week-old TH-MYCN þ / þ or WT mice compared with 6-week-old WT mice (Figure 3b ), thereby suggesting that the role of Bmi1 upregulation in neuroblastoma precursor cells may not be mediated by p19 ARF transcriptional repression.
Using an adenoviral vector expressing a Bmi1-specific short hairpin RNA, we demonstrated that knocking down Bmi1 in neuroblastoma precursor cells from 2-week-old TH-MYCN neuroblastoma precursor cells contributed to p53 downregulation and cell death resistance. Bmi1 appeared to be a more potent factor than MDM2 at the point of embryonal tumor initiation.
Bmi1 regulates p53 protein stability independent of MDM2 and ARF Bmi1 is a component of the Polycomb group multi-protein PRC1 complex, required to maintain the transcriptionally repressive state of several genes, including the Ink4a/ARF locus. It has been shown that when ARF expression is repressed by Bmi1, MDM2 is free to polyubiquitinate p53 and induce its proteasomal degradation. 19 We examined the hypothesis that Bmi1 modulated p53 protein stability in human neuroblastoma tumor cell lines. The p53 protein half-life was markedly increased following Bmi1 knockdown with specific small interfering RNA in human NBL-S (Figures 4a and b) and BE(2)C (Supplementary Figure S4) neuroblastoma cells, whereas, exogenous Bmi1 overexpression reduced p53 protein half-life (Figure 4c) . Importantly, when the same experiments were conducted in the presence of Nutlin-3A there was no change in the effect of Bmi1 on p53, indicating an MDM2-independent process (Figure 4d) . Additionally, the SHEP human neuroblastoma cell line, which is known to carry a homozygous deletion of the p14
ARF gene, 27 also demonstrated an increased p53 protein stability following Bmi1 knockdown ( Figures  4e and f) , thereby suggesting that the Bmi1 effect on p53 protein stability is also independent of p14 ARF transcriptional regulation. Together these results indicated that Bmi1 regulated p53 protein stability in an MDM2-and ARF-independent manner.
Bmi1 directly binds p53 and induces p53 polyubiquitination Bmi1 is known to enhance the E3 ubiquitin-ligase activity of Ring1A and Ring1B, and control the proteasomal degradation of a non-histone protein, topoisomerase 2a, 28 indicating that the Bmi1-induced phenotype can be mediated via mechanisms that do not involve transcriptional regulation. Consequently, we examined whether Bmi1 could bind p53 and directly induce its polyubiquitination. We first showed in two human neuroblastoma cell lines (NBL-S and SHEP) that endogenous p53 from whole-cell lysates was co-immunoprecipitated with Flag-tagged Bmi1 (Figure 5a ). We next performed glutathione S-transferase (GST) Pull-Down assays using GST fusion Ring1A and Ring1B proteins (produced in bacteria and purified on glutathione-sepharose beads, Supplementary Figure S5a ) and whole-cell extracts from SHEP cells either non-transfected or transfected with a p53-Flag expressing vector. These experiments demonstrated that the two Ring proteins also directly bound to endogenous or overexpressed p53 (Figure 5b ). In addition, in the presence of overexpressed Bmi1, p53 binding to both GST-Ring1A and GST-Ring1B increased slightly (Supplementary Figure S5b) , thereby suggesting that Bmi1 might facilitate this binding, possibly as a scaffold protein.
In order to assess whether Bmi1 can directly induce p53 polyubiquitination, we performed ex-vivo and in vitro ubiquitination assays. For ex-vivo assays, neuroblastoma cells were transfected with a HA-tagged ubiquitin-expressing vector or a control vector, together with a Flag-tagged Bmi1-expressing vector or a control vector. Proteasome-mediated degradation and MDM2-mediated p53 polyubiquitination were inhibited by treating the cells with MG132 and Nutlin-3A. The p53 protein was then immunoprecipitated from whole-cell lysates and analyzed by western blot using either HA-, p53-or Flag-specific antibodies. We observed increased p53 polyubiquitination in both NBL-S and p14 ARF -deleted SHEP neuroblastoma cells overexpressing Bmi1 (Figures 5c and e, right panels) . Conversely, Bmi1 knockdown markedly reduced p53 ubiquitination (Figures 5d and f) . We verified that these results were not due to a difference in p53 expression levels (Supplementary Figure S5c-f) . In addition, Bmi1 itself appeared to be mono-ubiquitinated (Figures 5c and e , left panels), as previously described. 29 In vitro ubiquitination reactions were performed using purified and eluted GST-tagged Bmi1, together with either GST-Ring1A or GST-Ring1B as E3 ligase complexes. The p53 substrate was Bmi1, MYCN and embryonal cancer initiation M Calao et al purified from whole SHEP protein extracts and incubated with ubiquitin reaction components including Ubiquitin, E1 (activating enzyme), E2 (conjugating enzyme) and E3 as indicated on Figure 5g . p53 ubiquitination was analyzed by western blot using anti-p53 antibodies. We showed that both Ring1A and Ring1B induced p53 mono-and di-ubiquitination, and that Bmi1 markedly increased the efficacy of the reaction (Figure 5g ). We also identified UbcH5a and UbcH5c as E2 enzymes involved in the reaction (Figure 5g ), whereas UbcH6 could not efficiently mediate Bmi1/Ring-dependent p53 ubiquitination (Supplementary Figure  S5g) . Collectively, these results demonstrated that the Bmi1/ Ring1A and Bmi1/Ring1B complexes acted as E3 ubiquitin ligases for p53 by directly binding p53 and inducing its multiubiquitination in vitro and polyubiquitination ex vivo.
MYCN protects precursor cells for medulloblastoma and leukemia from death due to trophic factor withdrawal We next examined the hypothesis that aberrant MycN expression in precursor cells for other embryonal cancer types might also result in resistance to trophic factor withdrawal. Hyperplasia of medulloblastoma precursor cells or GNPs precedes medulloblastoma tumorigenesis in Ptch1 þ / À mice in a similar manner to neuroblastoma precursor cells in TH-MYCN þ / þ mice. 8 GNPs from TH-MYCN þ / þ mice were infected with an adenoviral construct containing a Bmi1-specific, or a control (Ctl), short hairpin RNA (shRNA), subjected to serum withdrawal, and assessed for viability using bIII tubulin positivity.
offspring, which were then assessed for the comparative incidence of tumor-free survival, compared with parent genotypes. (e) Superior cervical and celiac ganglia were collected from mice on postnatal day 12. Sections of ganglia were stained with hematoxylin and eosin and examined with a light microscope for the presence of hyperplastic lesions. Shown are percentages of hyperplasiacontaining ganglia from mice of the indicated genotype (means ± s.e.m; n ¼ 12-15). The proportion of ganglia with neuroblast hyperplasias or rests (430 cell aggregates) from the offspring were determined by light microscopy from hematoxylin and eosin-stained tissue sections of paravertebral ganglia (***Po0.001, **Po0.01. All error bars represent means ± s.e.m.).
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1-week-old Ptch1
þ / À mice exhibited increased survival when their trophic factor, sonic hedgehog (Shh), was withdrawn from the culture medium. We transfected Ptch1 þ / À GNPs with a MycNspecific small interfering RNA (Supplementary Figure S6a) , and observed a significant increase in the level of apoptosis following Shh withdrawal, compared with control ( Figure 6a ). In agreement with previous studies suggesting a direct role for Bmi1 in medulloblastoma tumorigenesis, 30 we found increased Bmi1 expression in perinatal Ptch1 þ / À GNPs and tumor, compared with perinatal WT GNPs (Figure 6b) . Importantly, GNPs also failed to induce p53 following serum withdrawal (Figure 6c ). These data implicate inactivation of the p53 stress response in GNPs at the time of medulloblastoma tumor initiation.
Markers of the leukemic clone in pre-B lymphocytes can be detected perinatally in most children who much later develop acute lymphoblastic leukemia. 31 Thus, we examined the hypothesis that perinatal murine pre-B cells, dependent on the trophic factor interleukin-7 (IL-7) for survival ex vivo, might also demonstrate a survival benefit when forced to express MycN. Pre-B cells, purified from the bone marrow of 2-week-old normal mice 32 and infected with a retrovirus expressing MycN (Supplementary Figure S6b) , demonstrated enhanced colony forming ability following withdrawal of IL-7, in liquid and semisolid culture conditions, compared with vector only controls (Figure 6d) . In a comparison with control pre-B cells, we also observed reduced apoptosis after IL-7 withdrawal in MycNoverexpressing cells as measured by TUNEL staining (Figure 6e ), which correlated with a decreased p53 induction as shown by western blot (Figure 6f ).
DISCUSSION
Following organogenesis, embryonal cells produced in excess of requirements are deleted by mechanisms such as trophic factor insufficiency. 6 If this process is incomplete, embryonal cell rests may persist to later become cancerous, a theory suggested more than a century ago 33, 34 and more recently confirmed by murine and human studies. 7, 35, 36 Our findings have important implications for our understanding of rest cell persistence and embryonal tumorigenesis, and the links between normal embryogenesis and cancer.
Here, we showed that MycN overexpression caused resistance to death from trophic factor withdrawal in normal perinatal precursor cells for three different embryonal cancer types, in agreement with previous studies in neuroblastoma models. 37, 38 Importantly, we showed that this effect was transient in the perinatal period and correlated with increased Bmi1 mRNA expression, compared with mature postnatal cells. Moreover, Bmi1 mRNA expression was induced by MycN in a stepwise manner during tumorigenesis, consistent with a recent study showing that MycN induced Bmi1 transcription. 20 The presence of high Bmi1 levels in both cancer precursor cells and normal perinatal cells is consistent with its role in the regulation of stem cell maintenance and renewal, as well as in the development and progression of human cancers. 19 Normal differentiated cells have an equilibrium between the expression levels of pro-apoptotic and antiapoptotic proteins. In normal neural progenitor cells, medulloblastoma and neuroblastoma cells, this equilibrium appeared to be shifted towards repressed pro-apoptotic p53 stress responses, thereby impairing MycN capacity to sensitize cells for apoptosis. This is presumably because embryonal malignancies arise from progenitor cells, which are already proliferating as part of normal development. 39 Importantly, we have shown that Bmi1 knockdown in neuroblastoma precursor cells and normal perinatal cells restored p53 responses and death sensitivity. We hypothesize that transient Bmi1-mediated p53 downregulation in normal perinatal cells could have a protective value, as the embryonal (a, c, and e) Cells were treated with the inhibitor of protein synthesis cycloheximide (25 mg/ml) and lysed at the indicated times. Whole-cell extracts were analyzed by western blotting using anti-p53, -Bmi1 or -actin antibodies.
environment can be subjected to frequent stresses, such as hypoxia or nutrient deprivation. The protective function of Bmi1 during embryogenesis may be exploited during embryonal tumor initiation through persistent downregulation of p53 responses (Figure 7) .
The molecular mechanism so far proposed to explain Bmi1-mediated apoptosis regulation is via the repression of p19 ARF (p14 ARF in humans) transcription, consequent inhibition of MDM2 and stabilization of p53. However, we did not observe a decrease in p19
ARF mRNA levels synchronous with the increased Bmi1 levels in WT and TH-MYCN þ / þ perinatal ganglia cells. Moreover, the MDM2 inhibitor, Nutlin-3A, could not completely restore death sensitivity and p53 levels in neuroblastoma precursor cells. These observations suggested that an Ink4a/ARF-independent Figure 5 . Bmi1 Binds p53 and, together with Ring1A or Ring1B, directly induces p53 polyubiquitination. (a) SHEP and NBL-S cells were transfected with either a Bmi1-flag expressing vector or the corresponding empty vector. Whole-cell extracts were incubated with anti-flag antibodies to immunoprecipitate Bmi1. The immunoprecipitated samples, as well as the inputs, were analyzed by western blotting using antip53 or anti-flag antibodies. (b) Whole-cell extracts from SHEP cells overexpressing, or not, p53-flag were incubated with recombinant GST, GST-Ring1A or GST-Ring1B proteins produced in bacteria and purified on glutathione-sepharose beads. After incubation, these samples, as well the inputs (IN), were analyzed by western blotting using anti-p53 antibodies. (c, e) NBL-S (c) or SHEP (e) cells were transfected with either a Bmi1-flag expressing vector or a control vector, together with either an Ubiquitin-HA expressing vector or a control vector. Forty-eight hours after transfection, cells were treated with Nutlin (10 mM, 8 h) and MG132 (15 mM, 5 h), and lysed. Whole-cell extracts were incubated with anti-p53 antibodies. The immunoprecipitated samples, as well as the inputs, were analyzed by western blotting using anti-flag, -HA or -p53 antibodies. (d, f ) NBL-S (d) or SHEP (f ) cells were transfected with either a scrambled or a Bmi1-specific small interfering RNA (siRNA). After 24 h, the same cells were transfected with either an HA-ubiquitin expressing vector or a control vector. Twenty-four hours later, cells were treated with MG132 (15 mM, 5 h) and whole-cell extracts were incubated with anti-p53 antibodies. The immunoprecipitated samples, as well as the inputs were analyzed by western blotting using anti-HA or -p53 antibodies. (g) The p53 substrate purified from SHEP cells was incubated in ubiquitination reactions containing the indicated components, and products were analyzed by western blotting using anti-p53 antibodies.
mechanism was responsible for the Bmi1-mediated regulation of p53 levels that we observed, in agreement with recent studies in neural stem cells and several cancers. 40, 41 Here, for the first time, we found that Bmi1 directly bound, together with Ring1A and Ring1B, to the p53 protein and induced its polyubiquitination and subsequent degradation.
Although Bmi1 itself lacks E3 enzymatic activity, it can act as a dose-dependent modulator of Ring1B and Ring1A E3 ubiquitinligase activity. 29 However, in agreement with various reports showing that Bmi1 is the rate-limiting factor in the ubiquitination reactions mediated by the Ring proteins, 28, 29 we demonstrated that Bmi1 overexpression or knockdown was sufficient to, respectively, induce or inhibit p53 polyubiquitination and regulate p53 stability. In vitro, we showed that Bmi1 strongly increased both Ring1A-and Ring1B-mediated p53 mono-and di-ubiquitination, thereby suggesting that an E4 enzyme is necessary in vivo for the elongation of the ubiquitin chain primed by these two E3 ligase complexes, as previously shown for MDM2-mediated p53 polyubiquitination. 42, 43 Indeed, although known to directly induce p53 polyubiquitination, MDM2 does not polyubiquitinate p53 in vitro. Instead, it catalyzes the addition of single ubiquitin moieties to p53, thereby priming it for E4 enzymemediated ubiquitin chain elongation. 42, 43 Importantly, Bmi1 expression was necessary for neuroblastoma initiation in TH-MYCN transgenic mice in vivo. Although we and others 14 have previously demonstrated a role for MDM2 in Figure 6 . MYCN protects precursor cells for other embryonal malignancies from trophic factor withdrawal-induced death. (a) GNP from 1-week-old hemizygous Ptch1 þ / À knockout mice, or WT littermates, were cultured with and without their trophic factor, Shh, and evaluated for apoptosis using TUNEL immunofluorescent staining. Additionally, the same experiment was carried out after GNPs were transfected with a vector expressing an short hairpin RNA (shRNA), which blocked MYCN expression, or empty vector control. Bmi1, MYCN and embryonal cancer initiation M Calao et al embryonal cancer development, here we showed that the role of MDM2 in embryonal cancer initiation is less significant than the role played by Bmi1. Mdm2 mRNA levels were not significantly increased in normal perinatal cells or neuroblastoma precursor cells when compared with mature cells. TH-MYCN þ / þ mice crossed with Mdm2 þ / À hemizygote knockout mice demonstrated only a small decrease in neuroblast hyperplasia. Nutlin-3A treatment of perinatal ganglia from TH-MYCN þ / þ mice did not completely restore sensitivity to cell death after trophic factor withdrawal, whereas Bmi1 knockdown in the same cells had a much stronger effect. These findings are crucial for guiding future development of new drugs for neuroblastoma treatment or prevention.
The TP53 gene encoding the p53 protein is probably the most commonly mutated gene in human cancers, but it is rarely mutated in embryonal tumors. 11 However, inactivation of p53 contributes significantly to the development of these two tumors in specific animal models. 24, 44 Our findings demonstrate that p53 responses are markedly and transiently repressed by Bmi1, and to a much lesser extent MDM2, in normal perinatal precursor cells for medulloblastoma and neuroblastoma, providing a possible explanation for the lack of p53 gene deletions or mutations in embryonal cancer types. Moreover, our data indicate that reactivation of the p53 stress response through the inhibition of Bmi1 activity in precancer cells may be an effective prevention strategy for human embryonal cancer.
MATERIALS AND METHODS
Cell culture SHEP-S1, BE(2)-C, and NBL-S neuroblastoma cells and HEK293 embryonic kidney cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Mouse and rat primary ganglion cells were maintained in complete Neurobasal-A media (Invitrogen, Mount Waverley, VIC, Australia) on poly-D-lysine and laminin-coated coverslips (HD Scientific, Wetherill Park, NSW, Australia) in 24-well plates in the presence of 3.3 mM Aphidicolin (Sigma Aldrich, Castle Hill, NSW, Australia) and 50 ng/ml nerve growth factor (GroPep, Adelaide, SA, Australia). Mouse NHO 2 A, perpetuated from a TH-MYCN þ / þ mouse tumor, were grown in RPMI 1640 with 20% fetal calf serum-supplemented 2 mM L-glutamine, 1 mM sodium pyruvate, 1 Â nonessential amino acids and penicillin/ streptomycin (Invitrogen).
Mouse primary GNPs were grown in neurobasal media supplemented with 1% v/v N 2 , 1mM sodium pyruvate solution, 1% v/v penicillinstreptomycin (Invitrogen) and 20 ng/ml Shh (R&D systems, Minneapolis, MN, USA). Pre-B cells were grown in RPMI 1640 media (Gibco, Melbourne, Victoria, Australia) containing 10% fetal calf serum, 10 ng/ml recombinant mouse IL-7 (R&D systems) and 50 mM b Mercaptoethanol (Invitrogen).
Mouse models
TH-MYCN
þ / þ transgenic mice on a mixed C57BL/6J and 129 Â 1/SvJ genetic background, where the human MYCN cDNA is expressed in a tissue-specific manner under the influence of the rat tyrosine hydroxylase promoter, were a generous gift from Dr W Weiss at University of California, San Francisco. 22 The neuroblastoma tumor incidence for TH-MYCN mice is 30% at 13 weeks of age for hemizygotes and 100% at 6 weeks of age for homozygotes. For the cross between Bmi1 knockout mice and TH-MYCN transgenic mice, TH-MYCN transgenic mice on the 129 Â 1/SvJ genetic background were obtained from the Mouse Models of Human Cancers Consortium at National Cancer Institute-Frederick. Bmi1 þ / À mice 45 Figure 7 . A model for neuroblastoma initiation. Following migration from the neural crest to their final destination, both progenitor cells (neuroblasts, yellow) and post-mitotic neurons (orange) are produced in excess to final requirements. Only those cells that have differentiated and made appropriate connections are retained, other cells being deleted by apoptosis. The immature neurons die in large numbers as they compete for trophic factors (e.g. nerve growth factor (NGF)). We propose that MycN (red) and Bmi1 (purple) overexpression, as well as apoptosis pathway downregulation, are required for normal neural crest development. However, neuroblasts can persist pathologically postnatally, evading apoptotic mechanisms, due to transient repression of the p53 (green) stress response signal by Bmi1 and continued exposure to MycN. Further postnatal oncogenic events are required to progress from precancer cells to neuroblastoma. Downregulated proteins are represented in gray. Green and red arrows indicate upregulation and downregulation, respectively. knockout ( þ / À ) mice. All animal studies were pre-approved by the Institutional Animal Care and Use Committees at the four institutions.
Primary ganglia, GNP and Pre-B cell isolation Primary paravertebral ganglia tissue was isolated from 2-week or 6-weekold homozygous TH-MYCN þ / þ transgenic mice or WT littermates, and tumor tissue from 6-week-old TH-MYCN þ / þ mice as previously described. 7 GNPs were isolated from the cerebellum of 1-week-old Ptch1 þ / À mice or WT littermates. Tumor tissue was isolated from 20-week-old Ptc1 þ / À mice displaying signs of ataxia as previously described. 8 Conditions for the derivation and culture of bone marrow derived B cells were adapted from published work. 47 
Apoptosis assays
Apoptotic cell death of primary ganglia, GNPs and pre-B cells following growth factor withdrawal was measured by the TUNEL assay. In brief, the primary cultures were grown in the presence nerve growth factor, Shh or IL-7. The cells were then deprived of trophic factor for 24 h, fixed and incubated with the TUNEL reaction mixture (Roche, Sydney, NSW, Australia). The treated cells were washed and visualized using fluorescence microscopy. The proportion of TUNEL-positive cells was determined and expressed as a percentage of primary cells maintained in the trophic factor.
The cells were also incubated with for b-III tubulin (1:400) and caspaseactivated deoxyribonuclease (1:200) or apoptosis-inducing factor (1:100) antibodies (Chemicon, Temecula, CA, USA) for 1 h at room temperature, followed by Cy3 and Alexa 488 secondary antibodies for 30 min. The cells were then mounted using Vectorshield medium containing 4',6-diamidino-2-phenylindole and examined by fluorescence microscopy.
Ex vivo ubiquitination assays
For ex vivo ubiquitination assays, neuroblastoma cell lines were transfected with an HA-tagged Ubiquitin-expressing vector (or a control vector) either together with a Flag-Bmi1 expressing vector (or a control vector) or 24 h after transfection with a Bmi1-specific (or scrambled) small interfering RNA. Forty-eight hours after the first transfection, cells were pre-treated for 3 h with the MDM2 inhibitor Nutlin-3 A (10 mM) and then treated for five extra hours with the protease inhibitor MG132 (15 mM). Cells were lysed in Ubiquitin Lysis Buffer containing N-ethyl-maleimide, and protease and phosphatase inhibitors. Cell lysates were pre-incubated 1 h at 4 1C with an anti-p53 antibody and then over night at 4 1C with G Sepharose beads (Sigma, St Louis, MO, USA). After extensive washes with Ubiquitin Lysis Buffer, the immunoprecipitated samples, as well as inputs were resolved by sodium dodecyl sulfate-PAGE and analyzed by western blot using the indicated antibodies.
Statistics
Statistical analyses were performed with the Student's t-test for independent samples (nonparametric), and results are expressed as mean ± s.e. unless otherwise specified. P-value p0.05 was considered as statistically significant. Cell-based studies consisted of 4-12 independent experiments. In animal-based studies, n ¼ 5-10 animals per group.
